Chairman, CEO, and Founder
Over a decade of industry experience spanning executive management and corporate financing, Dr. Jacobs has developed a business with a robust intellectual property position. IMDx was founded out of what she believed was an underserved need in the industry: rapid and effective diagnostics to shrink the turnaround time between a patient presenting with an illness and a prescribed targeted treatment. Her first focus has been on healthcare-associated infections. By creating a company that offers inventive and rapid solutions to healthcare issues, Dr. Jacobs is fulfilling her goal of empowering physicians to make early, intelligent choices regarding patient treatment. In 2012 she was honored as one of Ten Outstanding Young Leaders by the Boston Chamber of Commerce, as well as a Woman to Watch by Mass High Tech. In 2011 she was named Best Entrepreneur for a non-service business of up to 100 employees in the eighth annual Stevie® Awards for Women in Business. In 2009 IMDx was presented the Frost & Sullivan award for Healthcare Innovation, Clinical Diagnostics for Molecular Diagnostics and Scientific American named Dr. Jacobs as one of the top 50 innovators in science and technology. She was also selected by the World Economic Forum as a member of the Forum of Young Global Leaders. Dr. Jacobs is considered a thought leader in the area of molecular diagnostics and has been featured in IVD Technology, PharmaVOICE, Fox Business News, CNBC Healthy Horizons and the Boston Herald's Women in Business. Dr. Jacobs holds an M.D. from Harvard Medical School, a B.Sc. in Biological Sciences with Honors in Developmental Neurobiology as well as a B.A. in Art History from Stanford University.
Back to top
Senior Vice President and General Counsel
Sarah Toomey has over a decade of experience in biotechnology and life sciences. Ms. Toomey heads the legal department at IMDx and is responsible for expansion of the IMDx portfolio, consisting of 8 issued patents and 75 pending patent applications across personalized medicine, optimized pathogen/disease detection, and diagnostic design. Ms. Toomey also plays an integral role in business development and oversight of corporate partnerships, serving as Alliance Manager for the current Abbott and QIAGEN partnerships and contributing to the completion of over $30MM in corporate partnership deals for IMDx. Ms. Toomey also heads the program management department at IMDx, developing and tracking project-related goals. After obtaining her B.S. in bacteriology from the University of Wisconsin-Madison, she worked at Merck as a research scientist in a microbiology lab. She later received her J.D. from Suffolk University and is registered to practice before the United States Patent and Trademark Office and admitted to practice in the Commonwealth of Massachusetts and the U.S. Court of Appeals for the Federal Circuit.
Back to top
Vice President, Research & Development
Dr. Exner joined IntelligentMDx in December of 2012 as Vice President of Research & Development. He has extensive experience developing diagnostic products and systems for both infectious disease and molecular genetic applications, having led the production and launch of numerous FDA cleared and CE marked products. He is a thought leader in the field of molecular diagnostics, and holds a number of patents in the area of molecular detection technologies. Dr. Exner previously served as Vice President of Research & Development for Focus Diagnostics, a wholly owned subsidiary of Quest Diagnostics Incorporated, and as the Director of Assay Development at Handylab Inc. (now owned by Becton, Dickinson and Company), both at which he developed sample-to-answer IVD molecular tests and systems using microfluidic technologies. He has also served in roles with increasing responsibility at Quest Diagnostics Nichols Institute where he led teams to produce over 75 molecular and serological products. Dr. Exner received his Ph.D. in Microbiology from the University of British Columbia, Vancouver, Canada, and is a board certified Diplomate of the American Board of Medical Microbiology.
Back to top
Vice PresidentQuality Assurance & Regulatory Affairs
Ms. Walker has over 25 years of experience in quality management. She joined IntelligentMDx in January 2012, coming from Siemens Healthcare Diagnostics, where she was the Vice President of Quality Assurance. At Siemens she was responsible for implementation and maintenance of the world wide quality system and managed a total staff of 165 employees. Prior to Siemens, Ms. Walker spent over 15 year at Nova Biomedical in increasing roles of responsibility, ending as a Senior Quality Control Manager. Ms. Walker obtained her BS in Medical Technology from Rochester Institute of Technology.
Back to top
Mr. Copeland joined IMDx in early 2013 bringing over 10 years of experience in finance coupled with an academic background in molecular genetics. Mr. Copeland has extensive experience in a wide range of finance functions, including financial analysis and advising, accounting, and investor relations. He has held managerial positions at several pharmaceutical companies, including Millennium and Ironwood, and comes to IMDx from Inspiration Biopharmaceuticals, where he served as Director of Strategic Analysis and Financial Planning. Mr. Copeland obtained his Bachelor’s Degree in molecular genetics from The Ohio State University and spent 4 years as a research associate at Harvard University before obtaining his Master’s Degree in Business Administration from Northeastern University.
Back to top
Director of Operations
Mr. Reinhart joined IntelligentMDx in June 2013 as Director of Operations. He has extensive experience producing medical devices, therapeutics, vaccines and fine chemicals in regulated industries. Mr. Reinhart previously served in Operations roles as Production Manager for Anika Therapeutics, Inc., Operations Manager at EMD Millipore, Inc., Deputy Director of Manufacturing at Sanofi Pasteur, and Operations and Process Engineering Manager at Proteome Systems, Inc. He has also served in engineering roles at Air Products and Chemicals, Inc., and Biopure, Inc. Mr. Reinhart received his B.S. in Chemical Engineering from The Pennsylvania State University, State College, PA and his M.S. in Biotechnology from Northeastern University, Boston, MA.
Back to top